companies > R > Roche Roche Roche buys Lonza’s Singapore unit for $360 million 02 September 2009 SC refuses to hear Roche's patent plea against Cipla 28 August 2009 Roche clinches Genentech deal for $47 billion 12 March 2009 Roche calls Genentech’s $112 a share demand unreasonable, may reach agreement on $95 a share 10 March 2009 Roche raises Genentech offer from $86.50 to $93 a share 07 March 2009 Genentech tells shareholders to reject Roche bid 24 February 2009 Sale of Genentech skin drug `Raptiva' suspended after 3 deaths 20 February 2009 Carl Icahn attempts to get nominees on Biogen board after blockbuster drug drags 07 February 2009 Roche lowers Genentech bid to $42 billion 30 January 2009 Roche confirms plans to acquire remaining 44 per cent in Genentech 21 October 2008 Genentech Says Employee Plan May Cost $371 Million 23 August 2008 Genentech rejects Roche’s $43.7-billion takeover offer as too low 13 August 2008 Roche bids for Genentech on Monday, acquires Mirus on Tuesday and Arius on Wednesday 25 July 2008 Roche makes a $43.7-billion bid for Genentech 21 July 2008 Delhi HC upholds ruling in Cipla-Roche cancer drug row 23 April 2008 Cipla to continue selling its version of Roche's lung cancer treatment drug 20 March 2008 Roche to acquire Ventana for $89.50 per share 23 January 2008 Roche takes Teva to court over generic osteoporosis drug 11 September 2007 Roche secures US court injunction for its Ventana bid 23 August 2007 Rebuffed by Ventana, Roche may increase its $3-billion bid 13 July 2007 Roche goes to court over Ventana''s poison-pill defence 05 July 2007 Roche makes hostile offer for Ventana 27 June 2007 Roche buys Toyama''s arthritis drug for $370 million 26 June 2007 Roche reports strong global sales for Tamiflu 27 April 2006 Roche grants Tamiflu licence to Hyderabad firm Hetero Drugs 24 December 2005 On the clinical trial trail 11 March 2005 Novartis acquires 20 per cent stake in Roche 08 May 2001  search domain-b    go
Legal Policy | Copyright © 1999-2009 The Information Company Private Limited. All rights reserved.